Country Club Trust Company n.a. held its stake in shares of Eli Lilly and Company (NYSE:LLY) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,927 shares of the company’s stock at the close of the second quarter. Country Club Trust Company n.a.’s holdings in Eli Lilly and were worth $241,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of Eli Lilly and by 3.3% during the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after purchasing an additional 2,181,701 shares during the period. BlackRock Inc. grew its stake in shares of Eli Lilly and by 2,628.5% during the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after purchasing an additional 59,978,664 shares during the period. State Street Corp grew its stake in shares of Eli Lilly and by 1.6% during the 1st quarter. State Street Corp now owns 42,363,935 shares of the company’s stock worth $3,563,230,000 after purchasing an additional 651,424 shares during the period. Geode Capital Management LLC grew its stake in shares of Eli Lilly and by 8.4% during the 1st quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock worth $764,597,000 after purchasing an additional 708,597 shares during the period. Finally, Janus Capital Management LLC grew its stake in shares of Eli Lilly and by 2.8% during the 1st quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock worth $733,731,000 after purchasing an additional 237,619 shares during the period. Institutional investors own 75.77% of the company’s stock.

In other news, major shareholder Lilly Endowment Inc sold 180,000 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the sale, the insider now directly owns 123,865,804 shares in the company, valued at $10,040,562,072.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 825,000 shares of company stock worth $68,456,650 over the last 90 days. Company insiders own 0.20% of the company’s stock.

A number of equities research analysts have recently commented on LLY shares. UBS AG cut shares of Eli Lilly and to a “hold” rating and set a $85.00 price objective on the stock. in a research note on Wednesday, July 26th. Jefferies Group LLC reaffirmed a “buy” rating and set a $93.00 price objective on shares of Eli Lilly and in a research note on Thursday, June 22nd. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $88.00 price objective on shares of Eli Lilly and in a research note on Sunday, May 21st. Berenberg Bank reaffirmed a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a research note on Friday, August 4th. Finally, Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective on the stock in a research note on Monday, July 17th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the stock. Eli Lilly and has a consensus rating of “Hold” and an average price target of $88.27.

Shares of Eli Lilly and Company (NYSE LLY) traded down 0.76% on Friday, reaching $82.44. The company’s stock had a trading volume of 5,374,504 shares. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $86.72. The company has a 50 day moving average of $80.89 and a 200 day moving average of $82.06. The stock has a market capitalization of $86.97 billion, a P/E ratio of 35.67 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same period in the prior year, the business earned $0.86 earnings per share. The business’s revenue was up 7.8% on a year-over-year basis. Equities research analysts expect that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th were given a $0.52 dividend. The ex-dividend date was Friday, August 11th. This represents a $2.08 annualized dividend and a dividend yield of 2.52%. Eli Lilly and’s dividend payout ratio is currently 90.04%.

ILLEGAL ACTIVITY WARNING: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/09/17/country-club-trust-company-n-a-holds-stake-in-eli-lilly-and-company-lly.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.